Skip to content

The effect of Huatuo Zao Pill on limb motor function after stroke

A Randomized controlled clinical study of Huatuo Zazao Pill in the treatment of limb motor dysfunction function after stroke

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000430
Enrollment
Unknown
Registered
2024-09-13
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

experimental group:routine stroke treatment, comprehensive rehabilitation training+Huatuo zaizao pills
control group:routine stroke treatment+comprehensive rehabilitation training

Sponsors

Gansu Provincial Rehabilitation Center Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? meeting the diagnostic criteria of Western medicine the patient was confirmed as cerebral infarction or cerebral hemorrhage by craniocerebral CT/MRI; ? stroke was the primary unilateral onset duration = 7 days duration = 90 days age = 30 years age = 80 years; ? Stable vital signs conscious no obvious cognitive impairment can cooperate with the completion of treatment and evaluation; ? Brunnstrom motor function of hemiplegia was evaluated as stage ? to ?; ? sign the informed consent and participate in the clinical trial voluntarily.

Exclusion criteria

Exclusion criteria: ? myodystonia not caused by stroke; ? Have a previous motor disability such as rheumatoid arthritis limb surgery joint deformity multiple sclerosis spinal cord injury or neuromuscular disease that affects limb sensation or movement; ? Patients with severe heart liver kidney endocrine diseases or secondary epilepsy or mental illness; ? Recent use of muscle relaxants or traditional Chinese and western sedatives; ? Patients whose Mini-Mental State Examination (MMSE) score is = 9 and cannot cooperate with examination and treatment; ? allergic to the investigational drug and its components; ? Pregnant or lactating women; ? The researchers did not consider it appropriate to participate.

Design outcomes

Primary

MeasureTime frame
FMA;

Secondary

MeasureTime frame
MAS;MWS;MBI;IEMG;

Countries

China

Contacts

Public ContactLi Yabin

Gansu Provincial Rehabilitation Center Hospital

424068699@qq.com18298358253

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026